Brighter’s Actiste® Receives Telecommunication Approval in Qatar

Report this content

Brighter AB (Publ.) announced today that the Qatari Communications Regulatory Authority has granted Actiste® type approval for the radio transmission element in the device. With this approval, both Actiste® (with insulin injection) and Actiste® Mini have now received telecom use approval in Qatar.

On 18 February 2021, Brighter announced that the company had signed a five-year distribution agreement with Al Danah Medical Company in Qatar regarding Brighter’s pioneering product portfolio for diabetes management Actiste® (“Actiste Service”).

“This approval is another significant commercialization milestone for the Actiste® portfolio in Qatar. We are very pleased that both Actiste® and Actiste® Mini have received approval for telecom use and we remain focused on completing all the remaining commercialization preparations to bring Brighter’s diabetes management platform to patients in need,” comments Christer Trägårdh, acting CEO of Brighter AB.

For more information, please contact:

Investor Relations

Certified Adviser

Brighter's Certified Adviser is Eminova Fondkommission AB, +46 (0)8 - 684 211 10,,

About Brighter AB (publ)
Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is a key to providing smarter care for chronic conditions. Our daily-care solutions are designed with a vision to facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers – aiming to improve quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter's quality management system is ISO-13485 certified. In 2019 the company won the Swecare Rising Stars Award. The Company's shares are listed on Nasdaq First North Growth Market/BRIG.

For more information, please visit our website at